vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and IMAX CORP (IMAX). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $125.2M, roughly 1.5× IMAX CORP). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 0.5%, a 12.8% gap on every dollar of revenue. On growth, IMAX CORP posted the faster year-over-year revenue change (35.1% vs -1.8%). IMAX CORP produced more free cash flow last quarter ($28.0M vs $24.6M). Over the past eight quarters, IMAX CORP's revenue compounded faster (25.8% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
IMAX Corporation is a Canadian production theatre company which designs and manufactures IMAX cameras and projection systems as well as performing film development, production, post-production and distribution to IMAX-affiliated theatres worldwide. Founded in Montreal in 1967, it has headquarters in the Toronto area, and operations in New York City and Los Angeles.
AMPH vs IMAX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $125.2M |
| Net Profit | $24.4M | $637.0K |
| Gross Margin | 46.8% | 57.6% |
| Operating Margin | 19.4% | 19.3% |
| Net Margin | 13.3% | 0.5% |
| Revenue YoY | -1.8% | 35.1% |
| Net Profit YoY | -35.7% | -88.0% |
| EPS (diluted) | $0.51 | $0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $125.2M | ||
| Q3 25 | $191.8M | $106.7M | ||
| Q2 25 | $174.4M | $91.7M | ||
| Q1 25 | $170.5M | $86.7M | ||
| Q4 24 | $186.5M | $92.7M | ||
| Q3 24 | $191.2M | $91.5M | ||
| Q2 24 | $182.4M | $89.0M | ||
| Q1 24 | $171.8M | $79.1M |
| Q4 25 | $24.4M | $637.0K | ||
| Q3 25 | $17.4M | $20.7M | ||
| Q2 25 | $31.0M | $11.3M | ||
| Q1 25 | $25.3M | $2.3M | ||
| Q4 24 | $38.0M | $5.3M | ||
| Q3 24 | $40.4M | $13.9M | ||
| Q2 24 | $37.9M | $3.6M | ||
| Q1 24 | $43.2M | $3.3M |
| Q4 25 | 46.8% | 57.6% | ||
| Q3 25 | 51.4% | 63.1% | ||
| Q2 25 | 49.6% | 58.5% | ||
| Q1 25 | 50.0% | 61.4% | ||
| Q4 24 | 46.5% | 52.2% | ||
| Q3 24 | 53.3% | 55.8% | ||
| Q2 24 | 52.2% | 49.4% | ||
| Q1 24 | 52.4% | 59.3% |
| Q4 25 | 19.4% | 19.3% | ||
| Q3 25 | 13.2% | 27.2% | ||
| Q2 25 | 24.2% | 15.6% | ||
| Q1 25 | 21.9% | 19.3% | ||
| Q4 24 | 24.2% | 10.3% | ||
| Q3 24 | 29.8% | 21.2% | ||
| Q2 24 | 30.3% | 3.2% | ||
| Q1 24 | 27.9% | 15.3% |
| Q4 25 | 13.3% | 0.5% | ||
| Q3 25 | 9.0% | 19.4% | ||
| Q2 25 | 17.8% | 12.3% | ||
| Q1 25 | 14.8% | 2.7% | ||
| Q4 24 | 20.4% | 5.7% | ||
| Q3 24 | 21.1% | 15.2% | ||
| Q2 24 | 20.8% | 4.0% | ||
| Q1 24 | 25.1% | 4.1% |
| Q4 25 | $0.51 | $0.02 | ||
| Q3 25 | $0.37 | $0.37 | ||
| Q2 25 | $0.64 | $0.20 | ||
| Q1 25 | $0.51 | $0.04 | ||
| Q4 24 | $0.74 | $0.09 | ||
| Q3 24 | $0.78 | $0.26 | ||
| Q2 24 | $0.73 | $0.07 | ||
| Q1 24 | $0.81 | $0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $151.2M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $337.9M |
| Total Assets | $1.6B | $894.0M |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $151.2M | ||
| Q3 25 | $276.2M | $143.1M | ||
| Q2 25 | $231.8M | $109.3M | ||
| Q1 25 | $236.9M | $97.1M | ||
| Q4 24 | $221.6M | $100.6M | ||
| Q3 24 | $250.5M | $104.5M | ||
| Q2 24 | $217.8M | $91.6M | ||
| Q1 24 | $289.6M | $81.0M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $337.9M | ||
| Q3 25 | $776.7M | $349.5M | ||
| Q2 25 | $757.5M | $320.4M | ||
| Q1 25 | $751.3M | $299.5M | ||
| Q4 24 | $732.3M | $299.5M | ||
| Q3 24 | $727.7M | $289.4M | ||
| Q2 24 | $713.3M | $267.2M | ||
| Q1 24 | $672.4M | $258.8M |
| Q4 25 | $1.6B | $894.0M | ||
| Q3 25 | $1.7B | $889.6M | ||
| Q2 25 | $1.6B | $868.6M | ||
| Q1 25 | $1.6B | $848.3M | ||
| Q4 24 | $1.6B | $830.4M | ||
| Q3 24 | $1.5B | $847.6M | ||
| Q2 24 | $1.5B | $827.4M | ||
| Q1 24 | $1.6B | $824.1M |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $29.4M |
| Free Cash FlowOCF − Capex | $24.6M | $28.0M |
| FCF MarginFCF / Revenue | 13.4% | 22.3% |
| Capex IntensityCapex / Revenue | 4.5% | 1.1% |
| Cash ConversionOCF / Net Profit | 1.35× | 46.11× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $118.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $29.4M | ||
| Q3 25 | $52.6M | $67.5M | ||
| Q2 25 | $35.6M | $23.2M | ||
| Q1 25 | $35.1M | $7.0M | ||
| Q4 24 | $29.0M | $11.5M | ||
| Q3 24 | $60.0M | $35.3M | ||
| Q2 24 | $69.1M | $35.0M | ||
| Q1 24 | $55.3M | $-11.0M |
| Q4 25 | $24.6M | $28.0M | ||
| Q3 25 | $47.2M | $64.8M | ||
| Q2 25 | $25.0M | $20.9M | ||
| Q1 25 | $24.4M | $5.3M | ||
| Q4 24 | $16.6M | $6.9M | ||
| Q3 24 | $46.2M | $34.2M | ||
| Q2 24 | $63.1M | $33.5M | ||
| Q1 24 | $46.5M | $-12.1M |
| Q4 25 | 13.4% | 22.3% | ||
| Q3 25 | 24.6% | 60.7% | ||
| Q2 25 | 14.3% | 22.8% | ||
| Q1 25 | 14.3% | 6.1% | ||
| Q4 24 | 8.9% | 7.4% | ||
| Q3 24 | 24.1% | 37.3% | ||
| Q2 24 | 34.6% | 37.6% | ||
| Q1 24 | 27.1% | -15.3% |
| Q4 25 | 4.5% | 1.1% | ||
| Q3 25 | 2.8% | 2.6% | ||
| Q2 25 | 6.1% | 2.6% | ||
| Q1 25 | 6.3% | 1.9% | ||
| Q4 24 | 6.7% | 5.0% | ||
| Q3 24 | 7.2% | 1.2% | ||
| Q2 24 | 3.3% | 1.8% | ||
| Q1 24 | 5.1% | 1.4% |
| Q4 25 | 1.35× | 46.11× | ||
| Q3 25 | 3.03× | 3.27× | ||
| Q2 25 | 1.15× | 2.06× | ||
| Q1 25 | 1.39× | 2.99× | ||
| Q4 24 | 0.76× | 2.16× | ||
| Q3 24 | 1.48× | 2.54× | ||
| Q2 24 | 1.82× | 9.78× | ||
| Q1 24 | 1.28× | -3.35× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
IMAX
| Technology Sales | $46.6M | 37% |
| Image Enhancement And Maintenance Services | $38.1M | 30% |
| Joint Revenue Sharing Arrangement | $20.4M | 16% |
| Maintenance | $16.3M | 13% |
| Finance Income | $2.8M | 2% |
| Other Content Solutions | $1.6M | 1% |
